Skip Navigation

Research

  • Robert and Renée Belfer Office for Dana-Farber Innovations

    Lab Dishes1

    Cancer Immunotherapy: Dana-Farber has licensed a large patent portfolio covering PD-1 and PD-L1 to multiple pharmaceutical companies

    Array of tubes in lab

    Acetylon Pharmaceuticals, a Dana-Farber start-up company, has launched Regenacy Pharmaceuticals, as Celgene Corporation acquires Acetylon

    Myles Brown, M.D.

    Myles Brown, MD, director of our Center for Functional Cancer Epigenetics, has been elected to The National Academy of Sciences

    Ken Anderson, MD, in his lab

    C4 Therapeutics, a successful Dana-Farber start-up company, is harnessing the innate power of the body to control the quality of proteins within cells

    We are committed to building collaborative relationships with companies, investors, and entrepreneurs.

    Collaboration Opportunities

Innovations

  • In the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI), our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through collaborations and relationships with industry.

    As a bridge between research and industry, BODFI is committed to building relationships with companies both large and small, with the investor community, and with entrepreneurs. Our goal is to create solutions.

  • At BODFI, we will:

    Email Us:
    General: innovation@dfci.harvard.edu
    Academic MTAs: mta@dfci.harvard.edu

  • In partnership with the Belfer Office of Dana-Farber Innovations, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest.
    View the list